
Travere Therapeutics (TVTX) Stock Forecast & Price Target
Travere Therapeutics (TVTX) Analyst Ratings
Bulls say
Travere Therapeutics is well-positioned for success due to their strong pipeline of rare disease therapies, including sparsentan for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN). The recent approval of sparsentan for FSGS, the first FDA-approved medication for this rare kidney disorder, greatly expands Travere's addressable market and should drive significant revenue growth in the coming years. With continued positive results from their ongoing clinical trials and a strong management team, we expect Travere's stock to continue performing well in the long term.
Bears say
Travere Therapeutics is expecting a rapid adoption of sparsentan, which could potentially increase the total number of addressable patients for Filspari to over 100,000 and generate peak US sales of more than $3 billion. However, there are risks including a potential need for additional capital and any delays or setbacks in the commercialization of their products, which could negatively impact the company's valuation. Additionally, while the company currently has a positive outlook, only time will tell if they are able to meet their projected timelines and sales potential.
This aggregate rating is based on analysts' research of Travere Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Travere Therapeutics (TVTX) Analyst Forecast & Price Prediction
Start investing in Travere Therapeutics (TVTX)
Order type
Buy in
Order amount
Est. shares
0 shares